Nephroprotective Potential of Polyalthia cerasoides: A Phytochemical and Pharmacological Review

Through processes like blood filtration, metabolic waste product excretion, and electrolyte balance management, the kidneys are vital organs that are crucial to preserving homeostasis in the human body [1]. Additionally, they support a number of physiological processes required for regular bodily function and help maintain fluid balance [1]. The kidneys are especially susceptible to injury because of their high metabolic activity and exposure to circulating pollutants.

Nephrotoxicity, which refers to the deterioration of kidney function due to exposure to harmful substances, has emerged as a significant clinical issue [1,2]. Drug-related nephrotoxicity ranks among the most prevalent causes of renal damage and is often linked to the administration of chemotherapeutic drugs, antibiotics, and other pharmaceuticals [2,3]. These medications can disrupt renal blood flow, trigger oxidative stress, and harm renal tubular cells, ultimately resulting in reduced kidney function [1,3]. The growing utilization of these treatments in medical practice has led to an increased occurrence of kidney-related conditions.

In recent times, there has been an increasing need for nephroprotective drugs that can avert or lessen kidney damage induced by medications and other harmful substances [4]. Traditional treatment methods frequently come with drawbacks, such as adverse effects and insufficient safeguarding against kidney injury. As a result, it is essential to investigate alternative methods that are both efficient and safe for prolonged application.

Medicinal plants are increasingly acknowledged as important sources of therapeutic compounds and have significantly contributed to both traditional and contemporary medicine [6,7]. Ethnopharmacological research underscores the importance of plant-derived substances in the discovery and development of drugs [6]. These plants possess a diverse array of bioactive components that demonstrate pharmacological properties such as antioxidant, anti-inflammatory, and cytoprotective activities [7]. Given their natural origins and relatively fewer side effects, medicinal plants are gaining attention for their potential in preventing and treating a variety of diseases, including renal disorders.

Polyalthia cerasoides (Roxb.) Bedd., a member of the Annonaceae family of medicinal plants, has drawn interest because of its varied pharmacological characteristics [8]. The plant is recognized to have important biological activity and has long been utilized for a variety of therapeutic applications. According to scientific research, Polyalthia cerasoides has antimutagenic, antiproliferative, and antioxidant qualities [8,9]. The presence of bioactive chemicals found in various plant sections is the main cause of these pharmacological actions.

Given that oxidative stress plays a significant role in the development of nephrotoxicity, Polyalthia cerasoides' antioxidant activity is especially significant [1]. Antioxidant substances can help shield renal cells from harm by scavenging free radicals and lowering oxidative damage. The plant's potential medicinal uses are further supported by its cytoprotective and antiproliferative qualities [9].

Although there aren't many direct research on Polyalthia cerasoides' nephroprotective benefits, its recognized pharmacological activity imply that it might be helpful in preserving kidney function. A solid foundation for additional research is provided by the existence of bioactive phytochemicals and their proven biological effects.

With an emphasis on Polyalthia cerasoides' phytochemical makeup, pharmacological characteristics, and possible function as a nephroprotective agent, this study attempts to gather and examine the body of research on the plant. The study also highlights the necessity of more investigation to confirm its effectiveness and investigate its mechanisms of action in kidney protection.

Phytochemical Profile:

 

 

Figure 1. Photographic representation of Polyalthia cerasoides (Roxb.) Bedd. (A): Tree, (B): bark, (C): flower

 

 

In order to prevent or lessen kidney injury, nephroprotection requires a number of biological processes. These methods mainly involve preventing cellular damage, reducing oxidative stress, and inhibiting inflammatory processes [22,24]. Exposure to toxic substances, metabolic disorders, and drug-induced effects are frequently linked to kidney damage. These factors affect normal cellular activities and compromise the structure and function of renal tissues [22].

Reducing oxidative stress is one of the main processes in nephroprotection [22]. An imbalance between the body's antioxidant defense system and the production of reactive oxygen species leads to oxidative stress. Reactive oxygen species overproduction damages cellular constituents such proteins, lipids, and DNA, which eventually impacts kidney function [22]. Thus, preventing nephrotoxicity and preserving kidney health depend on reducing oxidative stress.

Medicinal herbs include phytochemicals that are essential for strengthening antioxidant defense systems [24]. These substances aid in lowering oxidative damage to renal tissues by scavenging free radicals. Phytochemicals help maintain proper kidney function and protect cells by increasing the activity of natural antioxidant enzymes like catalase and superoxide dismutase [24]. One of the main ways that plant-based substances have nephroprotective effects is through this antioxidant process.The suppression of inflammation is another crucial mechanism [24]. Renal damage progresses as a result of inflammatory reactions, which are frequently seen in kidney illnesses. Cytokines and other mediators that cause tissue damage are released when inflammatory pathways are activated. These pathways are suppressed by phytochemicals with anti-inflammatory qualities, which lowers inflammation and stops more renal cell injury [24].

Another important component of nephroprotection is the prevention of apoptosis and cellular damage [22, 24]. Functional renal cells can be lost as a result of cell death pathways triggered by toxic substances and oxidative stress. Protective substances aid in preventing apoptosis, preserving membrane integrity, and stabilizing cellular structures. This helps to maintain the structure and functionality of the kidneys.

It has also been demonstrated that pharmacological and dietary therapies are crucial for kidney protection [23]. Numerous cellular pathways implicated in renal damage can be modulated by nutritional strategies and medicinal substances. These treatments may improve the kidney's defense mechanisms, lower oxidative stress, and affect metabolic processes [23]. These tactics are especially crucial in situations linked to aging and chronic renal disease, where the body's natural defenses may deteriorate.

Furthermore, one key method for achieving nephroprotection is the modification of signaling pathways [23]. Various molecular pathways regulate cell survival, inflammation, and oxidative stress responses. Renal damage can be decreased and overall renal function can be improved with interventions that target these pathways. This emphasizes how crucial it is to comprehend molecular pathways in order to create nephroprotective treatments that work.

In general, a variety of mechanisms, including as antioxidant activity, anti-inflammatory effects, and cellular injury prevention, are used to produce nephroprotection [22,24]. These defense systems are strengthened and renal health is supported by phytochemicals derived from medicinal plants [24]. By altering cellular pathways and minimizing damage, pharmacological and dietary methods can play a role [23]. The use of plant-based substances in the treatment and prevention of renal disorders is supported by these mechanisms.

Evidence from Related Plants

The pharmacological characteristics of medicinal plants in the Annonaceae family, including their possible role in nephroprotection, have been extensively researched [25]. According to a number of studies, plants in this family have bioactive chemicals that help prevent kidney injury. The significance of investigating related species for their therapeutic potential in renal diseases is supported by these findings.

Through various experimental techniques, such as in vitro, in vivo, and in silico studies, research on medicinal plants has shown that a number of species display nephroprotective action [25]. These studies demonstrate how chemicals originating from plants can lessen kidney damage brought on by medications, pollutants, and oxidative stress. These protective effects are largely due to the presence of phytochemicals that have anti-inflammatory and antioxidant properties.

Annona muricata, a significant member of the Annonaceae family, has demonstrated encouraging nephroprotective potential [26]. According to studies, this plant's phytochemicals help shield the kidneys from harm. The bioactive substances found in Annona muricata help to improve kidney function and lessen oxidative stress. These results imply that similar phytochemical compositions may provide plants in the same family similar medicinal qualities.

Annona muricata's nephroprotective capability lends credence to the idea that additional Annonaceae family members, like Polyalthia cerasoides, may have comparable biological activity [26]. It is fair to anticipate similar pharmacological effects because plants within a family frequently contain related classes of phytochemicals. This supports the theory that Polyalthia cerasoides may have nephroprotective qualities as well.

Numerous phytochemicals have been found to have important renal protective qualities in addition to particular plant research [27]. These substances include a number of classes of molecules derived from plants that have cytoprotective, anti-inflammatory, and antioxidant properties. The potential of these phytochemicals to prevent and treat kidney illnesses, such as renal cell carcinoma and other types of kidney damage, has been investigated.

Because they can target several pathways implicated in kidney damage, phytochemical-based treatments have drawn interest [27]. These substances can help preserve the kidneys by reducing oxidative stress, preventing inflammation, and controlling cellular functions. The application of these phytochemicals offers a crucial tactic for creating substitute medicinal substances for kidney-related illnesses.

Additionally, renal disorders have historically been treated using plant-based remedies in ancient medical systems [28]. Many medicinal plants have chemicals with nephroprotective potential, according to a classification of these plants based on their phytochemical composition. These plants' medicinal value is supported by the fact that they are utilized in a number of traditional methods for treating kidney-related disorders.

Important insights into the function of medicinal plants in the treatment of renal illness have been obtained through the merging of traditional knowledge with contemporary scientific study [28]. Research has shown that substances produced from plants may be viable options for creating novel nephroprotective medications. This emphasizes how crucial it is to carry out further study in this field.

The idea that plant-based chemicals have substantial nephroprotective potential is often supported by data from related plants, especially those in the Annonaceae family [25]. This data is further supported by the effects of Annona muricata that have been shown and the discovery of several phytochemicals that protect the kidneys [26,27]. The use of plant-based medicines in the treatment of renal illness is further supported by conventional medical procedures [28].

These findings collectively suggest that Polyalthia cerasoides, being a member of the same family and possessing similar phytochemical constituents, may also exhibit nephroprotective activity. To confirm its promise and determine its therapeutic uses, more experimental and clinical research is necessary.

Limitations of Current Evidence

The available scientific information about Polyalthia cerasoides' nephroprotective potential has significant limitations, despite the increased interest in medicinal plants for nephroprotection. The absence of direct experimental trials that explicitly assess its impact on renal function is one of the main drawbacks [29]. Rather than offering concrete proof of its function in nephroprotection, the majority of the material that is now accessible concentrates on broad pharmacological characteristics or research on related species. It is challenging to reach firm conclusions regarding its effectiveness in treating or preventing kidney disease because of this study gap.

The fact that a sizable amount of the current data comes from preclinical research is another key drawback [31, 32]. To assess biological activity and toxicity, these investigations are usually carried out utilizing animal models or in vitro systems. These investigations don't always accurately mimic human physiological conditions, even though they offer important preliminary insights into the mechanisms of action and possible treatment effects. Results may differ across experimental models and humans due to differences in metabolism, dose, and biological reactions. Because of this, results from preclinical research do not necessarily translate immediately to clinical settings.

Despite their widespread usage in medication research, preclinical animal models have intrinsic limitations when it comes to predicting human responses [31]. Results from animal experiments may not necessarily transition well to human trials, according to issues with external validity and reproducibility that have been brought to light. The trustworthiness of these investigations may also be impacted by variations in experimental design and methodology [32]. These restrictions highlight the importance of interpreting preclinical results cautiously when thinking about medicinal applications.

Additionally, a major obstacle to the confirmation of Polyalthia cerasoides' nephroprotective benefits is the lack of well-designed clinical trials [34, 35]. To assess the safety, effectiveness, and suitable dosage of medicinal medicines in people, clinical trials are crucial. It is impossible to produce conclusive proof for its usage in clinical practice without such research. Confirming the advantages found in preclinical research is hampered by the absence of human studies and randomized controlled trials.

Additionally, there are a number of difficulties with clinical research, such as problems with study design, sample size, and patient population diversity [34]. These elements may have an impact on the results and how they are interpreted. Furthermore, the reliability and generalizability of results may be impacted by limitations in the existing clinical trial methodology [35]. This makes it more difficult to validate plant-based treatments for renal disorders.

Another limitation is the lack of comprehensive data on safety and toxicity in humans. Despite the fact that medicinal plants are frequently regarded as harmless because of their natural nature, thorough toxicity assessments are required to guarantee their safe usage. The development of Polyalthia cerasoides as a therapeutic drug is limited by the lack of adequate clinical data on side effects and long-term safety profiles.

Overall, the current evidence regarding the nephroprotective potential of Polyalthia cerasoides is limited by the lack of direct experimental studies, reliance on preclinical data, and absence of well-designed clinical trials [29,31,32,34,35]. These drawbacks show that more thorough and methodical research is required to determine its effectiveness and safety, including controlled experimental experiments and clinical investigations. To advance Polyalthia cerasoides' development as a possible nephroprotective agent, these gaps must be filled.

FUTURE DIRECTIONS

Stronger scientific proof of Polyalthia cerasoides' nephroprotective potential should be the main goal of future study. Conducting in vivo investigations is a crucial prerequisite for assessing the biological activity of plant extracts in entire organisms [36]. Compared to in vitro investigations, in vivo studies offer a deeper comprehension of pharmacokinetics, pharmacodynamics, and total therapeutic benefits. The effectiveness of Polyalthia cerasoides in preventing or lessening kidney damage under experimental settings can be ascertained with the use of these research.

To confirm its therapeutic potential in people, well-designed clinical studies are required in addition to in vivo research [36]. Confirming the safety, effectiveness, and proper dosage of plant-based substances requires clinical research. These investigations will enhance the development of Polyalthia cerasoides as a nephroprotective drug by bridging the gap between experimental results and clinical applications.

The thorough examination of the molecular mechanisms underlying nephroprotection is another crucial subject for further research [37, 38]. To clarify how the plant protects kidney tissues, it is necessary to comprehend the underlying biochemical pathways. Research into gene expression, signaling pathways, and molecular targets might offer important insights into the mechanisms of action. These characteristics can be thoroughly investigated using sophisticated methods in pharmacology and molecular biology.

Another crucial area of study focus is the identification and isolation of Polyalthia cerasoides' active chemicals [37]. There are many different phytochemicals found in medicinal plants, but not all of them have the same therapeutic effects. Thus, identifying the involvement of particular bioactive chemicals in nephroprotection can be aided by isolating them and examining their individual actions. This strategy may also result in the creation of new medications based on substances produced from plants.Furthermore, research should focus on evaluating the toxicity and safety profile of Polyalthia cerasoides [39,40]. Systematic toxicity studies are required to guarantee the safe use of plant-based substances in humans, despite the fact that they are frequently regarded as safe. To evaluate any negative consequences, new toxicity testing techniques, such as contemporary prediction methodologies, can be used [39]. Before thinking about any therapeutic application, a thorough safety study is necessary.

The development of standardized extraction methods and quality control measures is also important for future studies. The composition and activity of phytochemicals might vary depending on plant material, extraction techniques, and environmental factors. Clinical development requires consistency and reliability in research findings, which standardization will help to ensure.Another essential stage in converting research into useful applications is clinical validation through well planned investigations [44,45]. Establishing the efficacy of Polyalthia cerasoides in human populations requires carefully planned clinical trials with suitable sample sizes, control groups, and validated outcome measures. Determining the application of study findings in actual healthcare settings is another benefit of validation studies.

Furthermore, integrating plant-based medicines with traditional treatment methods may be investigated in future studies. Combining natural compounds with existing drugs may enhance therapeutic outcomes and reduce side effects. These integrative methods may offer fresh approaches to better renal disease management.

Overall, future research on Polyalthia cerasoides should focus on conducting in vivo and clinical studies, understanding molecular mechanisms, identifying active compounds, and ensuring safety and toxicity evaluation [36–40]. Clinical validation through rigorous studies is essential for its successful application in healthcare [44,45]. The development of safe and efficient nephroprotective treatments based on medicinal plants will be aided by addressing these research topics.

DISCUSSION

Polyalthia cerasoides (Roxb.) Bedd. has drawn interest from scientists because of its varied pharmacological actions and rich phytochemical makeup, which may aid in nephroprotection. Important bioactive substances found in the plant include terpenoids, alkaloids, flavonoids, phenolic compounds, and labdane diterpenes, which have cytoprotective, anti-inflammatory, and antioxidant properties. By scavenging reactive oxygen species and shielding cellular components from harm, these phytochemicals are crucial in lowering oxidative stress. Since oxidative stress is one of the major mechanisms involved in nephrotoxicity, the antioxidant potential of Polyalthia cerasoides suggests its possible role in protecting kidney tissues from injury caused by drugs, toxins, and metabolic disturbances.

In addition to antioxidant activity, the anti-inflammatory properties of the plant may further contribute to renal protection by reducing inflammatory responses associated with kidney damage. Due to the presence of similar phytochemicals, studies on related species like Polyalthia longifolia and other members of the Annonaceae family also support the likelihood of similar nephroprotective benefits. By enhancing antioxidant defense systems, inhibiting inflammatory mediators, and preventing cellular damage and apoptosis, the combined action of these bioactive substances may aid in preserving renal function. Nevertheless, despite these encouraging results, the information that is now available is still scant and primarily derived from preclinical and phytochemical research. There are insufficient direct experimental and clinical investigations that explicitly assess Polyalthia cerasoides' nephroprotective efficacy. Therefore, to confirm its effectiveness and safety as a possible nephroprotective drug, more in vivo research, molecular studies, toxicity evaluations, and carefully planned clinical trials are needed.

CONCLUSION

The pharmacological actions of polyalthia cerasoides are attributed to a variety of phytochemical compounds, including terpenoids, alkaloids, phenolics, and flavonoids. Its anti-inflammatory and antioxidant qualities suggest possible defense against kidney damage brought on by inflammation and oxidative stress.

Additional evidence for its potential nephroprotective function comes from related annonaceae plants. The plant may protect the kidneys by preventing cellular damage, inhibiting inflammatory pathways, and scavenging free radicals. However, there is currently little direct experimental data on nephroprotection, and the majority of the evidence is based on phytochemical and preclinical investigations.one of the biggest obstacles to verifying its therapeutic efficacy and safety is the lack of standardized investigations and well-designed clinical trials. In order to confirm polyalthia cerasoides as a possible nephroprotective drug for upcoming therapeutic applications, more in vivo studies, molecular analyses, and clinical research are necessary.

REFERENCES

1. Kwiatkowska E, Domański L, Dziedziejko V, Kajdy A, Stefańska K, Kwiatkowski S. The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. International Journal of Molecular Sciences. 2021 Jun 6;22(11):6109.
2. Barnett LM, Cummings BS. Nephrotoxicity and renal pathophysiology: a contemporary perspective. Toxicological Sciences. 2018 Aug 1;164(2):379-90.
3. Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional chemotherapy nephrotoxicity. Advances in Chronic Kidney Disease. 2021 Sep 1;28(5):402-14.
4. Shamna JJ, Shijikumar AR. A brief study of nephrotoxicity and nephroprotective agents. Indian J Pharm Biol Res. 2020;8:09-13.
5. Alkandahri MY, Sadino A, Pamungkas BT, Oktoba Z, Arfania M, Yuniarsih N, Wahyuningsih ES, Dewi Y, Winarti SA, Dinita ST. Potential nephroprotective effect of kaempferol: biosynthesis, mechanisms of action, and clinical prospects. Advances in Pharmacological and Pharmaceutical Sciences. 2024;2024(1):8907717.
6. Süntar I. Importance of ethnopharmacological studies in drug discovery: role of medicinal plants. Phytochemistry Reviews. 2020 Oct;19(5):1199-209.
7. Srivastava AK. Significance of medicinal plants in human life. InSynthesis of medicinal agents from plants 2018 Jan 1 (pp. 1-24). Elsevier.
8. Tekuri SK, Pasupuleti SK, Konidala KK, Pabbaraju N. Pharmacological effects of Polyalthia cerasoides (Roxb.) Bedd.: A brief review. J Complement Med Res. 2019;10(1):38-49.

9. Ravikumar YS, Mahadevan KM, Usha BM, Manjunatha H. Antiproliferative, apoptotic, and antimutagenic properties of stem bark and seed fractions of Polyalthia cerasoides (Roxb.). Journal of Cancer Research and Therapeutics. 2021 Oct 1;17(6):1339-46.
10. Siddappa RY, Aditya Rao SJ, Usha BM, Verma B, Mahadevappa P. Anti-proliferative activity of labdane diterpenes isolated from polyalthia cerasoides and their molecular interaction studies. Current Drug Discovery Technologies. 2022 Sep 1;19(5):78-85.
11. Troper M. The logic of justification of judicial review. International Journal of Constitutional Law. 2003 Jan 1;1(1):99-121.
12. Misra DP, Agarwal V. Systematic reviews: challenges for their justification, related comprehensive searches, and implications. Journal of Korean medical science. 2018 Mar 19;33(12).
13. Andreasen J, Nørgaard B, Draborg E, Juhl CB, Yost J, Brunnhuber K, Robinson KA, Lund H. Justification of research using systematic reviews continues to be inconsistent in clinical health science—A systematic review and meta-analysis of meta-research studies. PLoS One. 2022 Oct 31;17(10):e0276955.
14. Tekuri SK, Pasupuleti SK, Konidala KK, Pabbaraju N. Pharmacological effects of Polyalthia cerasoides (Roxb.) Bedd.: A brief review. Journal of Complementary Medicine Research. 2019;10(1):38-49.
15. Tekuri SK, Pasupuleti SK, Konidala KK, Pabbaraju N. Pharmacological effects of Polyalthia cerasoides (Roxb.) Bedd.: A brief review. Journal of Complementary Medicine Research. 2019;10(1):38-49.
16. Chen YC, Chia YC, Huang BM. Phytochemicals from Polyalthia species: Potential and implication on anti-oxidant, anti-inflammatory, anti-cancer, and chemoprevention activities. Molecules. 2021 Sep 3;26(17):5369.
17. Zafar F, Asif HM, Shaheen G, Ghauri AO, Rajpoot SR, Tasleem MW, Shamim T, Hadi F, Noor R, Ali T, Gulzar MN. A comprehensive review on medicinal plants possessing antioxidant potential. Clinical and Experimental Pharmacology and Physiology. 2023 Mar;50(3):205-17.
18. Tekuri SK, Pasupuleti SK, Konidala KK, Pabbaraju N. Pharmacological effects of Polyalthia cerasoides (Roxb.) Bedd.: A brief review. Journal of Complementary Medicine Research. 2019;10(1):38-49.
19. Tekuri SK, Pasupuleti SK, Konidala KK, Pabbaraju N. Pharmacological effects of Polyalthia cerasoides (Roxb.) Bedd.: A brief review. Journal of Complementary Medicine Research. 2019;10(1):38-49.
20. Bisht D, Prakash D, Kumar R, Shakya AK, Shrivastava S. Phytochemical profiling and nephroprotective potential of ethanolic leaf extract of Polyalthia longifolia against cisplatin-induced oxidative stress in rat model. Journal of Ethnopharmacology. 2024 May 23;326:117922.
21. Ganta S, Amuru SR, Anchapakula SL, Sree S, Subramanyam K. Hepato and nephroprotective effects of six important medicinal plants against toxic oxidative stress. Med Plants-Int J Phytomed Relat Ind. 2023;15(1):13-25.
22. Kwiatkowska E, Domański L, Dziedziejko V, Kajdy A, Stefańska K, Kwiatkowski S. The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. International journal of molecular sciences. 2021 Jun 6;22(11):6109.
23. Andrianova NV, Buyan MI, Bolikhova AK, Zorov DB, Plotnikov EY. Dietary restriction for kidney protection: decline in nephroprotective mechanisms during aging. Frontiers in physiology. 2021 Jul 6;12:699490.
24. Dragoș D, Manea MM, Timofte D, Ionescu D. Mechanisms of herbal nephroprotection in diabetes mellitus. Journal of Diabetes Research. 2020;2020(1):5710513.
25. Sujana D, Saptarini NM, Sumiwi SA, Levita J. Nephroprotective activity of medicinal plants: A review on in silico-, in vitro-, and in vivo-based studies. Journal of Applied Pharmaceutical Science. 2021 Oct 3;11(10):113-27.
26. Ololade ZS, Onifade OF, Eze JC, Oyebanji OT, Olaniran AC, Anuoluwa IA, Idowu OO, Tommy BE. Integrative phytochemical, ligand structure based drug design nephroprotective potential of Annona muricata flower-petals. Natural Product Research. 2025 Oct 2;39(19):5431-6.
27. Bajalia EM, Azzouz FB, Chism DA, Giansiracusa DM, Wong CG, Plaskett KN, Bishayee A. Phytochemicals for the prevention and treatment of renal cell carcinoma: preclinical and clinical evidence and molecular mechanisms. Cancers. 2022 Jul 4;14(13):3278.
28. Rabizadeh F, Mirian MS, Doosti R, Kiani-Anbouhi R, Eftekhari E. Phytochemical classification of medicinal plants used in the treatment of kidney disease based on traditional Persian medicine. Evidence‐based Complementary and Alternative Medicine. 2022;2022(1):8022599.
29. Vicente-Vicente L, Casanova AG, Hernández-Sánchez MT, Pescador M, Lopez-Hernandez FJ, Morales AI. A systematic meta-analysis on the efficacy of pre-clinically tested nephroprotectants at preventing aminoglycoside nephrotoxicity. Toxicology. 2017 Feb 15;377:14-24.
30. Nowak N. Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities. Journal of Diabetes Investigation. 2020 Sep;11(5):1085-96.
31. Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials: part 2: potential alternatives to the use of animals in preclinical trials. Basic to Translational Science. 2020 Apr 1;5(4):387-97.
32. Negi S, Kumar S, Singh A. Preclinical in vivo drug development studies: limitations, model organisms, and techniques. InDrugs and a Methodological Compendium: From bench to bedside 2023 Sep 24 (pp. 149-171). Singapore: Springer Nature Singapore.
33. Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of translational medicine. 2018 Dec;16(1):304.
34. Kostis JB, Dobrzynski JM. Limitations of randomized clinical trials. The American journal of cardiology. 2020 Aug 15;129:109-15.
35. Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?. JACC: Basic to Translational Science. 2019 Nov;4(7):845-54.
36. Sujana D, Saptarini NM, Sumiwi SA, Levita J. Nephroprotective activity of medicinal plants: A review on in silico-, in vitro-, and in vivo-based studies. Journal of Applied Pharmaceutical Science. 2021 Oct 3;11(10):113-27.
37. Den Hartogh DJ, Tsiani E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies. Nutrients. 2019 Jul 17;11(7):1624.
38. Roger E, Boutin L, Chadjichristos CE. The role of connexin 43 in renal disease: insights from in vivo models of experimental nephropathy. International Journal of Molecular Sciences. 2022 Oct 28;23(21):13090.
39. Zhang R, Wen H, Lin Z, Li B, Zhou X. Artificial intelligence-driven drug toxicity prediction: Advances, challenges, and future directions. Toxics. 2025 Jun 23;13(7):525.
40. Krewski D, Andersen ME, Tyshenko MG, Krishnan K, Hartung T, Boekelheide K, Wambaugh JF, Jones D, Whelan M, Thomas R, Yauk C. Toxicity testing in the 21st century: progress in the past decade and future perspectives. Archives of toxicology. 2020 Jan;94(1):1-58.
41. Ahn B. Advances in insulin resistance—Molecular mechanisms, therapeutic targets, and future directions. International journal of molecular sciences. 2025 Mar 13;26(6):2574.
42. Wu M, Shu J. Multimodal molecular imaging: current status and future directions. Contrast media & molecular imaging. 2018;2018(1):1382183.
43. Zhang C, Sheng Y, Sun X, Wang Y. New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions. Cancer and Metastasis Reviews. 2023 Sep;42(3):891-925.
44. Yang C, Kors JA, Ioannou S, John LH, Markus AF, Rekkas A, de Ridder MA, Seinen TM, Williams RD, Rijnbeek PR. Trends in the conduct and reporting of clinical prediction model development and validation: a systematic review. Journal of the American Medical Informatics Association. 2022 May 1;29(5):983-9.
45. Sperrin M, Riley RD, Collins GS, Martin GP. Targeted validation: validating clinical prediction models in their intended population and setting. Diagnostic and prognostic research. 2022 Dec 22;6(1):24.